These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 38558796

  • 1. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, Yang L, Zhao C, Lu C, Dong Q, Li H, Quan C.
    Front Immunol; 2024; 15():1343531. PubMed ID: 38558796
    [Abstract] [Full Text] [Related]

  • 2. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L.
    J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
    [Abstract] [Full Text] [Related]

  • 3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 4. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 5. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T.
    JAMA Neurol; 2021 May 01; 78(5):558-567. PubMed ID: 33779698
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 01; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R, Negroski D, Wynn D, Sellers D, Bzdek KG, Lublin AL, Rawlings AM, Quach C, Wells DP, Dumlao M, Bora A, Ranno AE, Luo KL, Chavin J, Hua LH, Becker D.
    Mult Scler Relat Disord; 2023 Feb 01; 70():104472. PubMed ID: 36566698
    [Abstract] [Full Text] [Related]

  • 8. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, Gasperini C, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L.
    J Neurol; 2021 Aug 01; 268(8):2922-2932. PubMed ID: 33616742
    [Abstract] [Full Text] [Related]

  • 9. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK, Frederiksen JL, Nielsen HH, Torkildsen Ø, Eek C, Huang-Link Y, Haghighi S, Tsai JA, Kant M.
    Mult Scler Relat Disord; 2022 Jul 01; 63():103892. PubMed ID: 35696880
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S.
    Mult Scler Relat Disord; 2019 Nov 01; 36():101376. PubMed ID: 31473488
    [Abstract] [Full Text] [Related]

  • 11. Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
    Lorefice L, Pilotto S, Fenu G, Cimino P, Firinu D, Frau J, Murgia F, Coghe G, Cocco E.
    J Neurol Sci; 2022 Jul 15; 438():120292. PubMed ID: 35605316
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar 15; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 13. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V, Buron MD, Siersma V, Rasmussen PV, Illes Z, Kant M, Hilt C, Mezei Z, Roshanisefat H, Sejbæk T, Weglewski A, van Wingerden J, Geertsen SS, Bramow S, Sellebjerg F, Magyari M.
    PLoS One; 2021 Mar 15; 16(5):e0250820. PubMed ID: 34003862
    [Abstract] [Full Text] [Related]

  • 14. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis.
    Zhou R, Li H, Yang H, Jiang F, Cai H, Li J, Chen S, Fang L, Yin J, Zeng Q.
    Mult Scler Relat Disord; 2022 Feb 15; 58():103446. PubMed ID: 34929454
    [Abstract] [Full Text] [Related]

  • 15. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
    Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, Amico E, Italian MS register.
    Mult Scler Relat Disord; 2022 Feb 15; 58():103489. PubMed ID: 35032879
    [Abstract] [Full Text] [Related]

  • 16. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
    Mukhtar H, Yasmeen U, Siddiqa S, Sarfraz Z, Sarfraz A.
    Mult Scler Relat Disord; 2022 Sep 15; 65():104002. PubMed ID: 35779372
    [Abstract] [Full Text] [Related]

  • 17. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
    Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024 Sep 15; 124(4):86-96. PubMed ID: 38676683
    [Abstract] [Full Text] [Related]

  • 18. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 12; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 20. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.
    de Sèze J, Devy R, Planque E, Delabrousse-Mayoux JP, Vandhuick O, Kabir M, Gherib A.
    Mult Scler Relat Disord; 2021 Jan 12; 47():102659. PubMed ID: 33291032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.